N-Formyladriamycin | 76573-10-9

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 蒽环类药物
• 英文名称: N-Formyladriamycin
• 英文别名: N-[3-hydroxy-2-methyl-6-[[(1S,3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl]oxy]oxan-4-yl]formamide
• CAS: 76573-10-9
• 化学式: C₂₈H₂₉NO₁₂
• 分子量: 571.5
• InChiKey: HDZSJJZLQYFKQG-PHKCKUDBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  41
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  209
• 氢给体数：
  6
• 氢受体数：
  12

文献信息

• [EN] ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS<br/>[FR] COMPOSÉS CIBLANT DES RÉCEPTEURS HORMONAUX NUCLÉAIRES ANTICANCÉREUX
  申请人：NUVATION BIO INC

  公开号：WO2020232119A1

  公开（公告）日：2020-11-19

  The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

  该披露涉及从核类固醇受体结合物中衍生的抗癌化合物，以及含有这些化合物的产品，以及它们的使用和制备方法。
• [EN] HISTONE DEACETYLASE (HDAC) INHIBITORS TARGETING PROSTATE TUMORS AND METHODS OF MAKING AND USING THEREOF<br/>[FR] INHIBITEURS D'HISTONE DÉSACÉTYLASE (HDAC) CIBLANT LES TUMEURS DE LA PROSTATE ET PROCÉDÉS POUR LES PRÉPARER ET LES UTILISER
  申请人：GEORGIA TECH RES INST

  公开号：WO2012050868A1

  公开（公告）日：2012-04-19

  Compounds of Formula (I), and methods of making and using thereof, are described herein; wherein AR is an aryl group, ZBG is a Zinc Binding Group, and other substituents are as defined herein. The compounds can be administered as a pharmaceutically acceptable salt, prodrug, or solvate. The compounds may be useful to treat and/or prevent hyperproliferative disorders which may include hormone sensitive and hormone refractory prostate cancers. The compounds can be formulated with a pharmaceutically acceptable carrier and, optionally one or more pharmaceutically acceptable excipients, for enteral or parenteral administration.

  本文描述了Formula (I)的化合物及其制备和使用方法；其中AR是芳基基团，ZBG是锌结合基团，其他取代基如本文所定义。这些化合物可以作为药学上可接受的盐、前药或溶剂形式进行给药。这些化合物可能有助于治疗和/或预防可以包括激素敏感和激素耐药的前列腺癌等高增殖性疾病。这些化合物可以与药学上可接受的载体以及选择性地与一个或多个药学上可接受的赋形剂配制，用于肠道或静脉注射给药。
• [EN] ANTHRACYCLINE PRODRUGS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] PROMÉDICAMENTS D'ANTHRACYNE ET PROCÉDÉS DE PRODUCTION ET D'UTILISATION DE CES DERNIERS
  申请人：UNIV COLORADO REGENTS

  公开号：WO2016176332A1

  公开（公告）日：2016-11-03

  Therapeutically effective prodrug compounds for the prevention and treatment of cancer and pharmaceutical compositions containing these compounds as well as methods of making and using these compounds.

  用于预防和治疗癌症的具有治疗效果的前药化合物，以及含有这些化合物的药物组合物，以及制备和使用这些化合物的方法。
• Targeted Drug-Formaldehyde Conjugates and Methods of Making and Using the Same
  申请人：Koch H. Tad

  公开号：US20070275911A1

  公开（公告）日：2007-11-29

  The invention provides a prodrug platform technology for improving the therapeutic value of a variety of parent drug compounds by altering and improving drug characteristics such as aqueous solubility, hydrolytic stability, therapeutic index, toxicity profile, pharmacolcinetics and selectivity while allowing the potential for synthetic elaboration. The prodrug platform is particularly well suited for targeting therapeutic drugs, including anti-tumor drugs and antibiotics, to specific receptors on target cells (e.g., cancer cells and bacteria). The platform is a technology for providing an improved, preactivated form of a therapeutic drug, and for optionally targeting such drug to target cells or biological molecules. The invention is broadly applicable to many different therapeutic drugs, as well as to a variety of diseases and conditions, including a variety of forms of cancer and bacterial infections.

  本发明提供了一种前药平台技术，通过改变和改进药物特性，如水溶性、水解稳定性、治疗指数、毒性谱、药代动力学和选择性，从而提高各种原始药物化合物的治疗价值，同时允许潜在的合成扩展。该前药平台特别适用于将治疗药物，包括抗肿瘤药物和抗生素，定向靶向到目标细胞（例如癌细胞和细菌）上的特定受体。该平台是一种提供改进的、预激活形式的治疗药物的技术，并可选择性地将该药物定向到目标细胞或生物分子。本发明广泛适用于许多不同的治疗药物，以及多种癌症和细菌感染等不同疾病和病况。
• METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF
  申请人：Koch Tad H.

  公开号：US20110135618A1

  公开（公告）日：2011-06-09

  The invention provides therapeutically effective compounds for the prevention and treatment of cancer and pharmaceutical compositions containing these compounds as well as methods of using and administering these compounds. The invention also includes methods of activating a prodrug of these therapeutically effective compounds by the administration of a peptide-directed targeting construct that delivers a prodrug-activating enzyme to a target activation site.

  本发明提供了预防和治疗癌症的治疗有效化合物，以及含有这些化合物的制药组合物，以及使用和管理这些化合物的方法。本发明还包括通过给靶向肽构造物输送一种前药激活酶到目标激活位点来激活这些治疗有效化合物的前药的方法。